Roivant Reports Positive Phase 3 Results for Uveitis Drug
Brepocitinib met the primary endpoint in both trials, and Priovant plans to seek expanded approval in the first half of 2027.
Makkler Newsroom · Oct 21, 07:28 PM · 1 min read
Roivant Sciences Ltd. ROIV
NASDAQHealth TechnologyUnited States
$39.53-0.46 (-1.15%)
Market closed· · USD · Data may be delayed
- Day's range
- 39.1639.82
- 52-week range
- 19.9642.50
Financial health
– / 5
Analyst view · 15 firms
Buy13 buy · 2 hold · 0 sell
Avg. target $50.82 (+28.6%)
Prices may be delayed and are for informational purposes only - not investment advice.